Vadim Y Dudkin

USPTO Granted Patents = 16 (Patent Applications = 4)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 7.6

ph-index = 5

Forward Citations = 63(Granted Patents)

Location History:

New York, NY (US) (2009)
Lansdale, PA (US) (2009 - 2015)
Chalfont, PA (US) (2015 - 2016)
West Point, PA (US) (2015 - 2021)

Company Filing History:

7 out of 2,405

Merck Sharp + Dohme Corp.

patents

5 out of 138

Sirna Therapeutics, Inc.

patents

2 out of 512

Sloan-kettering Institute for Cancer Research

Sima Therapeutics, Inc.

patents

Years Active: 2009-2021

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11117917 - Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides (2021-09-14),

2. 10221205 - Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides (2019-03-05),

3. 10214742 - Tetragalnac containing conjugates and methods for delivery of oligonucleotides (2019-02-26),

4. 9840531 - Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides (2017-12-12),

5. 9655976 - Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides (2017-05-23),

6. 9540639 - Tetragalnac containing conjugates and methods for delivery of oligonucleotides (2017-01-10),

7. 9428492 - Secondary alcohol substituted triazoles as PDE10 inhibitors (2016-08-30),

8. 9200001 - Triazolyl PDE10 inhibitors (2015-12-01),

9. 9062059 - Pyrimidine PDE10 inhibitors (2015-06-23),

10. 8993779 - Positive allosteric modulators of MGLUR2 (2015-03-31),

11. 8975286 - Ether benzotriazole derivatives (2015-03-10),

12. 8785481 - Ether benzotriazole derivatives (2014-07-22),

13. 8765784 - Positive allosteric modulators of MGLUR2 (2014-07-01),

14. 7645454 - Prostate specific antigens and uses thereof (2010-01-12),

15. 7531181 - Gp120 specific antigens and uses thereof (2009-05-12),

Title: Spotlight on Inventor Vadim Y Dudkin

Introduction:

Vadim Y Dudkin, a prolific inventor based in Lansdale, PA, has made significant contributions to the field of biotechnology with a total of 16 patents to his name. His innovative work has revolutionized the delivery of oligonucleotides, with a focus on enhancing the efficacy of targeted therapies.

Latest Patents:

Vadim's latest patents, Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides, showcase his expertise in developing modular compositions that include oligonucleotides, tetraGalNAc ligands, linkers, peptides, and other enhancing agents. This cutting-edge technology holds great promise for advancing precision medicine and personalized treatments.

Career Highlights:

Having worked with esteemed companies such as Merck Sharp & Dohme Corporation and Sirna Therapeutics, Inc., Vadim has honed his skills and expertise in the biopharmaceutical industry. His collaborative efforts have led to groundbreaking inventions that have the potential to transform the way we approach therapeutic interventions.

Collaborations:

Throughout his career, Vadim has collaborated with talented individuals such as David Tellers and Steven L Colletti, further enriching the innovative ecosystem in which he operates. Together, they have pushed the boundaries of scientific discovery and brought forth solutions that address unmet medical needs.

Conclusion:

Inventor Vadim Y Dudkin's relentless pursuit of excellence and commitment to advancing biotechnology make him a standout figure in the field of innovation. His remarkable patents and collaborations underscore his dedication to driving meaningful change in healthcare and beyond. As he continues to push the boundaries of what is possible, Vadim undoubtedly stands as a beacon of inspiration for aspiring inventors in the realm of biopharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.